Induction of Ferroptosis by ATF3 Elevation Alleviates Cisplatin Resistance in Gastric Cancer by Restraining Nrf2/Keap1/xCT Signaling

Overview

Journal Cell Mol Biol Lett

Publisher Biomed Central

Specialties Biochemistry
Cell Biology
Molecular Biology

Date 2021 Jun 8

PMID 34098867

Citations 97

Authors

Dazhi Fu

Chunxiao Wang

Lei Yu

Rui Yu

Affiliations

Soon will be listed here.

Abstract

Background: Currently, resistance against cisplatin (DDP) is a frequent problem for the success of advanced gastric carcinoma (GC) chemotherapy. Here, we sought to investigate the function of activating transcription factor 3 (ATF3) n GC chemoresistance.

Methods: Expression of ATF3 was determined in GC cell lines (MNK45, SGC7901, and BGC823) and cisplatin (DDP)-resistant cells (SGC7901/DDP and BGC823/DDP). Biological informatics was performed to analyze ATF3 expression and prognosis in GC patients. Cisplatin resistance was evaluated. Ferroptosis was detected after ATF3 transfection of cells. The underlying molecular mechanism was also investigated.

Results: Transcripts of ATF3 were decreased in GC cells and GC tissues. Kaplan-Meier plotter analysis revealed that ATF3 expression was positively related to the overall survival of GC patients. In particular, lower levels of ATF3 were observed in cisplatin-resistant SGC7901/DDP and BGC823/DDP relative to their parental cells. Notably, ATF3 elevation sensitized cisplatin-resistant cells to cisplatin. Mechanically, compared with parental cells, SGC7901/DDP and BGC823/DDP cells exhibited lower ferroptosis evident by lower ROS, MDA and lipid peroxidation and higher intracellular GSH levels. However, ATF3 elevated ferroptosis in SGC7901/DDP and BGC823/DDP cells. Intriguingly, ATF3 overexpression together with ferroptosis activator erastin or RSL3 treatment further enhanced ferroptosis and cisplatin resistance; however, the ferroptosis suppressor liproxstatin-1 reversed the function of ATF3 in ferroptosis and cisplatin resistance. Additionally, cisplatin-resistant cells exhibited stronger activation of Nrf2/Keap1/xCT signaling relative to parental cells, which was restrained by ATF3 up-regulation. Importantly, restoring Nrf2 signaling overturned ATF3-mediated ferroptosis and cisplatin resistance.

Conclusion: ATF3 may sensitize GC cells to cisplatin by induction of ferroptosis via blocking Nrf2/Keap1/xCT signaling, supporting a promising therapeutic approach for overcoming chemoresistance in GC.

Citing Articles

Reversal of chemotherapy resistance in gastric cancer with traditional Chinese medicine as sensitizer: potential mechanism of action.

Zhou C, Wu K, Gu M, Yang Y, Tu J, Huang X Front Oncol. 2025; 15:1524182.

PMID: 40052129 PMC: 11882405. DOI: 10.3389/fonc.2025.1524182.

USP2 reversed cisplatin resistance through p53-mediated ferroptosis in NSCLC.

Gong Y, Li R, Zhang R, Jia L BMC Med Genomics. 2025; 18(1):39.

PMID: 40011884 PMC: 11866681. DOI: 10.1186/s12920-025-02108-5.

Exosomes secreted by ATF3/Nrf2-mediated ferroptotic renal tubular epithelial cells promote M1/M2 ratio imbalance inducing renal interstitial fibrosis following ischemia and reperfusion injury.

Tang Q, Xie J, Wang Y, Dong C, Sun Q Front Immunol. 2025; 16:1510500.

PMID: 39975560 PMC: 11835872. DOI: 10.3389/fimmu.2025.1510500.

An integrative analysis of ASCL1 in breast cancer and inhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axis.

Yang X, Li Y, Peng Y, Chang Y, He B, Zhang T Front Immunol. 2025; 16:1546794.

PMID: 39963143 PMC: 11830715. DOI: 10.3389/fimmu.2025.1546794.

Yang Y, Yu S, Liu W, Zhuo Y, Qu C, Zeng Y Cancer Drug Resist. 2025; 8:1.

PMID: 39935430 PMC: 11813627. DOI: 10.20517/cdr.2024.151.

References

Liang C, Zhang X, Yang M, Dong X . Recent Progress in Ferroptosis Inducers for Cancer Therapy. Adv Mater. 2019; 31(51):e1904197. DOI: 10.1002/adma.201904197. View

Guan Z, Chen J, Li X, Dong N . Tanshinone IIA induces ferroptosis in gastric cancer cells through p53-mediated SLC7A11 down-regulation. Biosci Rep. 2020; 40(8). PMC: 7953492. DOI: 10.1042/BSR20201807. View

Jeddi F, Soozangar N, Sadeghi M, Somi M, Samadi N . Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/promotion and chemoresistance. DNA Repair (Amst). 2017; 54:13-21. DOI: 10.1016/j.dnarep.2017.03.008. View

Chen C, Ge C, Liu Z, Li L, Zhao F, Tian H . ATF3 inhibits the tumorigenesis and progression of hepatocellular carcinoma cells via upregulation of CYR61 expression. J Exp Clin Cancer Res. 2018; 37(1):263. PMC: 6208028. DOI: 10.1186/s13046-018-0919-8. View

Brown S, Sekhar K, Rachakonda G, Sasi S, Freeman M . Activating transcription factor 3 is a novel repressor of the nuclear factor erythroid-derived 2-related factor 2 (Nrf2)-regulated stress pathway. Cancer Res. 2008; 68(2):364-8. DOI: 10.1158/0008-5472.CAN-07-2170. View

Yin X, Wolford C, Chang Y, McConoughey S, Ramsey S, Aderem A . ATF3, an adaptive-response gene, enhances TGF{beta} signaling and cancer-initiating cell features in breast cancer cells. J Cell Sci. 2010; 123(Pt 20):3558-65. PMC: 2951469. DOI: 10.1242/jcs.064915. View

Petryszyn P, Chapelle N, Matysiak-Budnik T . Gastric Cancer: Where Are We Heading?. Dig Dis. 2020; 38(4):280-285. DOI: 10.1159/000506509. View

Fan Z, Wirth A, Chen D, Wruck C, Rauh M, Buchfelder M . Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis. 2017; 6(8):e371. PMC: 5608917. DOI: 10.1038/oncsis.2017.65. View

Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X . Ferroptosis: process and function. Cell Death Differ. 2016; 23(3):369-79. PMC: 5072448. DOI: 10.1038/cdd.2015.158. View

10.

Roh J, Kim E, Jang H, Park J, Shin D . Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Cancer Lett. 2016; 381(1):96-103. DOI: 10.1016/j.canlet.2016.07.035. View

11.

Hao Z, Ao J, Zhang J, Su Y, Yang R . ATF3 activates Stat3 phosphorylation through inhibition of p53 expression in skin cancer cells. Asian Pac J Cancer Prev. 2014; 14(12):7439-44. DOI: 10.7314/apjcp.2013.14.12.7439. View

12.

Kim S, Song N, Bahn G, Chang S, Yun U, Ku J . Atf3 induction is a therapeutic target for obesity and metabolic diseases. Biochem Biophys Res Commun. 2018; 504(4):903-908. DOI: 10.1016/j.bbrc.2018.09.048. View

13.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

14.

Dixon S, Lemberg K, Lamprecht M, Skouta R, Zaitsev E, Gleason C . Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012; 149(5):1060-72. PMC: 3367386. DOI: 10.1016/j.cell.2012.03.042. View

15.

Wang Q, Chen Q, Zhu L, Chen M, Xu W, Panday S . JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells. Oncogenesis. 2017; 6(7):e353. PMC: 5541709. DOI: 10.1038/oncsis.2017.57. View

16.

Shin D, Kim E, Lee J, Roh J . Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic Biol Med. 2018; 129:454-462. DOI: 10.1016/j.freeradbiomed.2018.10.426. View

17.

Zhu Y, He D, Bo H, Liu Z, Xiao M, Xiang L . The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway. Oncogene. 2019; 38(32):6065-6081. DOI: 10.1038/s41388-019-0858-7. View

18.

Zhang H, Deng T, Liu R, Ning T, Yang H, Liu D . CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020; 19(1):43. PMC: 7045485. DOI: 10.1186/s12943-020-01168-8. View

19.

Zhao W, Sun M, Li S, Chen Z, Geng D . Transcription factor ATF3 mediates the radioresistance of breast cancer. J Cell Mol Med. 2018; 22(10):4664-4675. PMC: 6156394. DOI: 10.1111/jcmm.13688. View

20.

Lou J, Zhao L, Huang Z, Chen X, Xu J, Tai W . Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer. Phytomedicine. 2020; 80:153370. DOI: 10.1016/j.phymed.2020.153370. View